Silverback Therapeutics Forecast, price target & analysts
Silverback Therapeutics Target price 2025 - Analyst rating & recommendation
Silverback Therapeutics Classifications & Recommendation:
Silverback Therapeutics Price Target
| Target Price | $30.60 |
| Price | $18.20 |
| Potential |
68.13%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Silverback Therapeutics 2026 .
The average Silverback Therapeutics target price is $30.60.
This is
68.13%
register free of charge
$42.00
130.77%
register free of charge
$26.26
44.29%
register free of charge
|
|
| A rating was issued by 12 analysts: 11 Analysts recommend Silverback Therapeutics to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Silverback Therapeutics stock has an average upside potential 2026 of
68.13%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 89.15 | 85.33 |
| 297,066.67% | 4.28% | |
| EBITDA Margin | -3.34% | -176.06% |
| 100.00% | 5,167.03% | |
| Net Margin | 8.97% | -172.82% |
| 100.00% | 2,025.86% |
8 Analysts have issued a sales forecast Silverback Therapeutics 2025 . The average Silverback Therapeutics sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Silverback Therapeutics EBITDA forecast 2025. The average Silverback Therapeutics EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Silverback Therapeutics Analysts have issued a net profit forecast 2025. The average Silverback Therapeutics net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.08 | -1.50 |
| 114.04% | 1,975.00% | |
| P/E | negative | |
| EV/Sales | 17.72 |
8 Analysts have issued a Silverback Therapeutics forecast for earnings per share. The average Silverback Therapeutics EPS is
This results in the following potential growth metrics and future valuations:
Silverback Therapeutics...
Current Silverback Therapeutics Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Scotiabank |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
| Raymond James |
Locked
➜
Locked
|
Locked | Jan 14 2025 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Jan 13 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Oct 08 2024 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Sep 20 2024 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Sep 16 2024 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Sep 09 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Scotiabank:
Locked
➜
Locked
|
Mar 07 2025 |
|
Locked
Raymond James:
Locked
➜
Locked
|
Jan 14 2025 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Jan 13 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Oct 08 2024 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Sep 20 2024 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Sep 16 2024 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Sep 09 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
